KU-0063794 5 mg | 98.35%
TargetMol
KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2.
More Information Supplier PageSearch Results
KU-0063794 50 mg | 98.35%
TargetMol
KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2.
More Information Supplier PageKU-0063794 25 mg | 98.35%
TargetMol
KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2.
More Information Supplier PageKU-0063794 10 mg | 98.35%
TargetMol
KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2.
More Information Supplier PageBortezomib 10 mg | 98.00%
TargetMol
Bortezomib (PS-341) is a potent 20S proteasome inhibitor (Ki: 0.6 nM, in a cell-free assay).
More Information Supplier PageBortezomib
Bortezomib 100 mg | 98.00%
TargetMol
Bortezomib (PS-341) is a potent 20S proteasome inhibitor (Ki: 0.6 nM, in a cell-free assay).
More Information Supplier PageBortezomib
Ramatroban 50 mg | 99.96%
TargetMol
Ramatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.
More Information Supplier PageRamatroban
Ramatroban 25 mg | 99.96%
TargetMol
Ramatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.
More Information Supplier PageRamatroban
Ramatroban 10 mg | 99.96%
TargetMol
Ramatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.
More Information Supplier PageRamatroban
Ramatroban 100 mg | 99.96%
TargetMol
Ramatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.
More Information Supplier PageRamatroban